Patents by Inventor Chin-Tarng Lin
Chin-Tarng Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10487119Abstract: A method of peptide histochemical diagnosis to detect the peptide binding protein in the cancer tissue is described. This peptide binding specifically to tumor cells is linked to the dextran coated iron oxide nanoparticle. The peptide linked dextran coated iron oxide nanoparticle can be used to bind to the formalin-fixed and paraffin-embedded tumor surgical specimens, and the method of present disclosure can be used to evaluate the efficacy of peptide-targeted chemotherapy for treatment of cancer patients.Type: GrantFiled: April 26, 2017Date of Patent: November 26, 2019Assignee: NATIONAL TAIWAN UNIVERSITYInventors: Chin-Tarng Lin, Han-Chung Wu
-
Publication number: 20170283468Abstract: The present invention provides a method of peptide histochemical diagnosis to detect the peptide binding protein in the cancer tissue. This peptide binding specifically to tumor cells is linked to the dextran coated iron oxide nanoparticle. The peptide linked dextran coated iron oxide nanoparticle can be used to bind to the formalin-fixed and paraffin-embedded tumor surgical specimens, and the method of present invention can be used to evaluate the efficacy of peptide-targeted chemotherapy for treatment of cancer patients.Type: ApplicationFiled: April 26, 2017Publication date: October 5, 2017Inventors: CHIN-TARNG LIN, HAN-CHUNG WU
-
Publication number: 20150111226Abstract: The present invention provides a method of peptide histochemical diagnosis to detect the peptide binding protein in the cancer tissue. This peptide binding specifically to tumor cells is linked to the dextran coated iron oxide nanoparticle. The peptide linked dextran coated iron oxide nanoparticle can be used to bind to the formalin-fixed and paraffin-embedded tumor surgical specimens, and the method of present invention can be used to evaluate the efficacy of peptide-targeted chemotherapy for treatment of cancer patients.Type: ApplicationFiled: January 27, 2014Publication date: April 23, 2015Applicant: National Taiwan UniversityInventors: Chin-Tarng Lin, Han-Chung Wu
-
Patent number: 8541543Abstract: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. Novel treatment strategies derived from increased knowledge of molecular oncology are constantly being developed to cure this disease. Here, we used phage display to identify novel peptides, including (SP94), which binds specifically to HCC cells. In vitro, the phage clone PC94 binds to HCC cell lines. In vivo, PC94 homed specifically to tumor tissues but not to normal visceral organs in SCID mice bearing human HCC xenografts. The homing ability could be competitively inhibited by synthetic peptide, SP94. PC94 localized to tumor tissues but could not be detected in SP94-competed tumor tissues or in normal organs. In addition, PC94 recognized the tumor tissue but not non-tumor tissue in surgical specimens from HCC patients, with a positive rate of 61.3% (19/31).Type: GrantFiled: November 18, 2008Date of Patent: September 24, 2013Assignee: Academia SinicaInventors: Han-Chung Wu, Chin-Tarng Lin, Albert Lo
-
Patent number: 8415453Abstract: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target lung cancer and were identified by phage display. Targeting phage PC5-2 and synthetic peptide SP5-2 were both able to recognize human pulmonary tumor specimens from lung cancer patients. In SCID mice bearing NSCLC xenografts, the targeting phage was able to target tumor masses specifically. When the peptide was coupled to liposomes containing the anti-cancer drugs vinorelbine or doxorubicin, the efficacy of these drugs against human lung cancer xenografts was improved, the survival rate increased, and the drug toxicity was reduced.Type: GrantFiled: April 13, 2007Date of Patent: April 9, 2013Assignees: Academia Sinica, National Taiwan UniversityInventors: Han-Chung Wu, Chin-Tarng Lin, De-Kuan Chang
-
Patent number: 8088887Abstract: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target neovasculature and were identified by in vivo phage display. One such peptide, SP5-52, recognized the neovasculature of multiple tumors in SCID mice, but did not target normal blood vessels. This peptide also binds to blood vessels of human lung cancer biopsy specimens. Liposomes comprising SP5-52 and doxorubicin enhanced the efficacy of the drug against multiple human cancer xenografts in SCID mice.Type: GrantFiled: April 13, 2007Date of Patent: January 3, 2012Assignees: Academia Sinica, National Taiwan UniversityInventors: Han-Chung Wu, Chin-Tarng Lin, Tong-Young Lee, Szu-Yao Kuo
-
Patent number: 7901877Abstract: The present invention provides genetic markers, SOX5 and SPARC, for distant metastasis and poor prognosis of detection of the high risk potential for cancer patients. In addition, the present invention also provides a method to predict the risk potential for cancer patients with distant metastasis and poor prognosis. This method comprises obtaining a tissue sample from a patient; evaluating the expression levels of the SOX5 and/or SPARC genetic markers in the sample; and comparing the expression levels of genetic markers with those of non-cancerous tissues. The patient is determined to have the high risk of distant metastasis or poor prognosis when the expression level of SOX5 is higher, or when the expression level of SPARC is lower, than that of non-cancerous tissue.Type: GrantFiled: October 16, 2007Date of Patent: March 8, 2011Assignee: National Taiwan UniversityInventors: Chin-Tarng Lin, Han-Chung Wu, Dah-Yeou Huang
-
Publication number: 20090136418Abstract: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. Novel treatment strategies derived from increased knowledge of molecular oncology are constantly being developed to cure this disease. Here, we used phage display to identify novel peptides, including (SP94), which binds specifically to HCC cells. In vitro, the phage clone PC94 binds to HCC cell lines. In vivo, PC94 homed specifically to tumor tissues but not to normal visceral organs in SCID mice bearing human HCC xenografts. The homing ability could be competitively inhibited by synthetic peptide, SP94. PC94 localized to tumor tissues but could not be detected in SP94-competed tumor tissues or in normal organs. In addition, PC94 recognized the tumor tissue but not non-tumor tissue in surgical specimens from HCC patients, with a positive rate of 61.3% (19/31).Type: ApplicationFiled: November 18, 2008Publication date: May 28, 2009Inventors: Han-Chung Wu, Chin-Tarng Lin, Albert Lo
-
Publication number: 20090054363Abstract: The present invention provides genetic markers, SOX5 and SPARC, for distant metastasis and poor prognosis of detection of the high risk potential for cancer patients. In addition, the present invention also provides a method to predict the risk potential for cancer patients with distant metastasis and poor prognosis. This method comprises obtaining a tissue sample from a patient, evaluating the expression levels of the SOX5 and/or SPARC genetic markers in the sample; and comparing the expression levels of genetic markers with those of non-cancerous tissues. The patient is determined to have the high risk of distant metastasis or poor prognosis when the expression level of SOX5 is higher, or when the expression level of SPARC is lower, than that of non-cancerous tissue.Type: ApplicationFiled: October 16, 2007Publication date: February 26, 2009Inventors: Chin-Tarng Lin, Han-Chung Wu, Dah-Yeou Huang
-
Publication number: 20080220409Abstract: Antigens and B-cell epitopes derived from dengue virus type 1 are provided. The antigens are specifically immunoreactive with sera from individuals infected with dengue virus type 1 but not reactive with sera from healthy individuals and individuals infected with dengue virus type 2. The antigens and epitopes are useful for development of diagnostic kits and reagents, and are useful tools as well in determining whether an individual is infected with dengue virus type 1, and for distinguishing infection from dengue virus type 2.Type: ApplicationFiled: March 8, 2007Publication date: September 11, 2008Applicant: NATIONAL TAIWAN UNIVERSITYInventors: Han-Chung Wu, Chin-Tarng Lin, Yun-Ching Chen
-
Publication number: 20080193375Abstract: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target lung cancer and were identified by phage display. Targeting phage PC5-2 and synthetic peptide SP5-2 were both able to recognize human pulmonary tumor specimens from lung cancer patients. In SCID mice bearing NSCLC xenografts, the targeting phage was able to target tumor masses specifically. When the peptide was coupled to liposomes containing the anti-cancer drugs vinorelbine or doxorubicin, the efficacy of these drugs against human lung cancer xenografts was improved, the survival rate increased, and the drug toxicity was reduced.Type: ApplicationFiled: April 13, 2007Publication date: August 14, 2008Inventors: Han-Chung Wu, Chin-Tarng Lin, De-Kuan Chang
-
Publication number: 20080193510Abstract: The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target neovasculature and were identified by in vivo phage display. One such peptide, SP5-52, recognized the neovasculature of multiple tumors in SCID mice, but did not target normal blood vessels. This peptide also binds to blood vessels of human lung cancer biopsy specimens. Liposomes comprising SP5-52 and doxorubicin enhanced the efficacy of the drug against multiple human cancer xenografts in SCID mice.Type: ApplicationFiled: April 13, 2007Publication date: August 14, 2008Inventors: Han-Chung Wu, Chin-Tarng Lin, Tong-Young Lee, Szu-Yao Kuo
-
Patent number: 7238665Abstract: The present invention provides a peptide marker targeting to nasopharyngeal carcinoma (NPC) cells and application thereof. The peptide binds specifically to the cell surface of NPC cells. After conjugated with liposome containing chemotherapeutic drugs, such peptides deliver chemotherapeutic drugs to the tumor cells specifically and destruct tumor cells without damaging normal tissues and organs. Furthermore, such peptide is applied as a detector in the development of NPC diagnosis kit.Type: GrantFiled: March 9, 2004Date of Patent: July 3, 2007Assignee: National Taiwan UniversityInventors: Han-Chung Wu, Chin-Tarng Lin, Tong-Young Lee
-
Publication number: 20050026860Abstract: Disclosed is a nucleolin antisense oligonucleotide for inhibition of tumor cell proliferation. The nucleolin antisense oligonucleotide comprising 20 nucleotides is complementary to the nucleolin mRNA. When the nucleolin antisense oligonucleotide hybridizes to nucleolin mRNA, it is effective in suppression of nucleolin RNA synthesis and the corresponding protein expression, which subsequently arrests the growth rate of tumor cells. The nucleolin antisense oligonucleotide is effective in inhibition of nucleolin expression of tumor cells in vitro and in vivo. Therefore, the nucleolin antisense oligonucleotide can be used as a therapeutic agent for inhibition of tumor cell proliferation.Type: ApplicationFiled: March 9, 2004Publication date: February 3, 2005Inventors: Chin-Tarng Lin, Han-Chung Wu
-
Publication number: 20050010036Abstract: The present invention provides a peptide marker targeting to nasopharyngeal carcinoma (NPC) cells and application thereof. The peptide binds specifically to the cell surface of NPC cells. After conjugated with liposome containing chemotherapeutic drugs, such peptides deliver chemotherapeutic drugs to the tumor cells specifically and destruct tumor cells without damaging normal tissues and organs. Furthermore, such peptide is applied as a detector in the development of NPC diagnosis kit.Type: ApplicationFiled: March 9, 2004Publication date: January 13, 2005Inventors: Han-Chung Wu, Chin-Tarng Lin, Tong-Young Lee